ArticleJTO clinical and research reports2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.
Surbhi Singhal et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.